openPR Logo
Press release

CD Bioparticles Releases New Block Copolymer Micelles for Drug Delivery Research

01-12-2021 11:09 AM CET | Health & Medicine

Press release from: CD Bioparticles

As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles launches a series of block copolymer micelles for global researchers to help solve the challenges faced in the studies such as limited drug-loading efficiency and yield, unpredictable or uncontrollable degradation rate of the drug-loading cargo, or uncontrollable drug delivery profile. These newly released products are applicable for a variety of potential usages, like biocompatible and biodegradable nanomaterials and bulk material fabrications, drug-delivery cargos with controllable delivery profile, and hydrogels with sol-gel transition useful for reversible encapsulation and delivery.

Many new products are released in the block copolymer micelles portfolio, such as Triblock Copolymers, which are vinylically reactive for binding into radical chain synthesized polymers, and AB Diblock Copolymers. For the latter products, the Acrylate-polycaprolactone-b-poly(ethylene glycol)-alkyne, for instance, is a biofunctional amphiphilic block copolymer with alkyne group at the end of PEG and acrylate at the end of polycaprolactone. ACRL-PCL-PEG-Alkyne is used to prepare micelles or nanoparticles with alkyne on the micelle surface for bioconjugation via click chemistry and acrylate in the micelle core for crosslinking. Hydrophobic drugs is encapsulated in the PCL core for targeted drug delivery.

Researchers now are accessible to a series of block copolymer for functional micelles fabrications, and gain lots of benefits such as degradable block copolymer with controllable degradation rate for sustainable release, controllable nanostructure for the assembly, cationic copolymers useful for gene delivery, bock copolymer assembled nanoparticles with controllable size and controllable core-shell ratio, and end-group functionalized block copolymers, useful for crosslinking and conjugation.

"When you're lack of cell-specific or tissue-specific targeting for nanomedicines, or functional groups for further modification/conjugation/crosslinking, or you want to get rid of tedious chemical synthesis and purification, CD Bioparticles will be a good choice for you," said Dr. Robin J. Watts, the product portfolio manager of CD Bioparticles. "CD Bioparticles is committed to developing quality drug delivery products and fulfilling our global clients’ needs, and these block copolymer micelles are added to our product portfolio of biopolymers & synthetic polymers, aiming to provide our customers more selection and value for reliable outcome."

For more detailed information on block copolymer micelles or biopolymers & synthetic polymers, please contact CD Bioparticles directly.

CD Bioparticles
Richard J. Gray
contact@cd-bioparticles.com

About CD Bioparticles

CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. It specializes in a range of formulation and drug delivery technologies, from conventional liposomes, PEGylated liposomes for drug delivery to polymer microspheres and nanoparticles for enhanced drug delivery. It provides contract services of drug delivery formulation developments for basic research, formulation feasibility studies, process development and scale-up, formulation characterization, analytical and nonclinical services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CD Bioparticles Releases New Block Copolymer Micelles for Drug Delivery Research here

News-ID: 2223610 • Views: 207

More Releases from CD Bioparticles

CD Bioparticles Expands Its Biodegradable Polymers Portfolio with Dendrimers
As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles recently introduces a series of dendrimers for research use, such as DMPA-G1-TMP-Acetylene, DMPA-G1-TMP-Azide, DMPA-G1-TMP-Carboxyl, and DMPA-G1-TMP-NHBOC. These biodegradable polymers can be used in theranostics, biosensors, optics, adhesives and coatings. With customized delivery strategies, precise designs and modifications of drugs or drug-contained cargos, and advanced technical platforms, CD Bioparticles can help scientists to solve problems in the
CD Bioparticles Releases Chitosans for Research Use
As a leading manufacturer and supplier of various drug delivery products and services, CD Bioparticles launches a series of chitosans for global research communities to support drug delivery studies. These new chitosans and derivatives are with various water solubility, and scientists now are accessible to products like CInd™ analogous hyaluronic acid chitosan, CInd™ carboxymethyl chitosan, CInd™ chitosan azelate and glycol chitin. One new product in this new release is the CInd™
First-class Chelating Agents Covering Full Range Are Available at CD Bioparticle …
Chelating agents are chemical compounds that react with metal ions to form a stable, water-soluble complex. They are also known as chelants, chelators, or sequestering agents. Chelating agents have a ring-like center which forms at least two bonds with the metal ion allowing it to be excreted. Due to the rising demand for cleaning formulations, the market will witness a growing trend in the need for chelating agents, which are

All 4 Releases


More Releases for PEG

PEG-12 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-12 Dimethicone market analysis, which studies the PEG-12 Dimethicone's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “PEG-12 Dimethicone Market 2020-2025” Research Report categorizes the global PEG-12 Dimethicone market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
PEG-10 Dimethicone Market: Competitive Dynamics & Global Outlook 2025
LP INFORMATION recently released a research report on the PEG-10 Dimethicone market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global PEG-10 Dimethiconemarket by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of PEG-10 Dimethiconemarket, market definition, overview, industry opportunities and trends, investment
Application of PEG In Click Chemistry
Polyethylene glycol (PEG) is a biocompatible, synthetic, hydrophilic polyether compound that has many applications, mostly in the medical industry, but also in the chemical and industrial sectors. The synthesis of PEG is done by polymerizing ethylene oxide, the main ingredient in antifreeze, using a ring-opening technique, which allows for PEGs of a range of molecular weights and molecular weight distributions to be constructed. This range in weights is what makes
What Are PEG Linkers?
Hydrophilic poly(ethylene glycol) or PEG-linkers are particularly attractive as a linker for conjugation. Water solubility, lack of toxicity; low immunogenicity and well defined chain lengths and molecular weights are specific characteristics of PEG moieties relevant to pharmaceutical applications. Hydrophilic linkers The link between the antibody and the cytotoxic agent plays a critical role in development of antibody-drug conjugates. The nature of the linker can significantly affect the potency, selectivity, and the pharmacokinetics of
Biochempeg developed a series of PEG compounds used for Semaglutide
Type 2 diabetes is the most common form of diabetes. Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes. It reduces blood sugar via increasing the production of insulin. Biochempeg has developed and can supply some key intermediates of Semaglutide. Semaglutide(trade names: Rybelsus,Ozempic) is a medication for the treatment of type 2 diabetes. It was discovered in 2012, by a team of researchers
Global PEG Stearate Market Huge Growth Opportunity between 2020-2025
LP INFORMATION recently released a research report on the PEG Stearate market analysis, which studies the PEG Stearate's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "PEG Stearate Market 2020-2025" Research Report categorizes the global PEG Stearate market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth